Lilly’s New Anti-Amyloid Play Hinges On Tau Bet
Redesigned Phase III Trial May Confirm Phase II Donanemab Results
TRAILBLAZER-ALZ met the primary, but not most secondary endpoints. Lilly said efficacy of its amyloid-clearing agent depends on tau levels at baseline and reductions in some parts of the brain.
